$LLY
Eli Lilly and Company · NYSE · Healthcare
- Market cap
- 1.14T
- Volume
- 2.27M
- P/E
- 42.75
- Day range
- 1257.62 – 1307.92
- 52w range
- 809.63 – 1321.21
- Analyst target
- 1331.55
AI Summary
Generating a unique summary for LLY…
AI-generated for information only — not investment advice.
Share this ticker
$LLY -2.54% at 1273.46 Stanley Druckenmiller and 4 other tracked billionaires hold it. $JNJ $NTRA $BHC https://billionairestrading.com/stocks/LLY
Company summary
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Institutional ownership
Institutions hold 85.36% · insiders 0.16% · 5,886 institutions
| Holder | Shares | Value | % held | Reported |
|---|---|---|---|---|
| Lilly Endowment, Inc | 90.07M | $114.70B | 9.57% | 2026-09-30 |
| Blackrock Inc. | 67.54M | $86.01B | 7.17% | 2026-06-30 |
| Vanguard Capital Management LLC | 53.53M | $68.17B | 5.69% | 2026-06-30 |
| PNC Financial Services Group, Inc. | 51.32M | $65.36B | 5.45% | 2026-06-30 |
| State Street Corporation | 36.22M | $46.12B | 3.85% | 2026-06-30 |
| FMR, LLC | 28.46M | $36.25B | 3.02% | 2026-06-30 |
| Capital Research Global Investors | 20.87M | $26.58B | 2.22% | 2026-06-30 |
| Vanguard Portfolio Management LLC | 20.86M | $26.56B | 2.22% | 2026-06-30 |
| Geode Capital Management, LLC | 20.31M | $25.87B | 2.16% | 2026-06-30 |
| Morgan Stanley | 16.23M | $20.66B | 1.72% | 2026-06-30 |
Hedge fund & billionaire activity
Insider transactions
| Insider | Role | Transaction | Shares | Date |
|---|---|---|---|---|
| SULZBERGER GABRIELLE | Director | Stock Award(Grant) at price 1240.34 per share. | 3.00 | 2026-10-19 |
| LUCIANO JUAN R | Director | Stock Award(Grant) at price 1240.34 per share. | 12.00 | 2026-10-19 |
| ALVAREZ RALPH | Director | Stock Award(Grant) at price 1240.34 per share. | 10.00 | 2026-10-19 |
| FYRWALD J. ERIK | Director | Stock Award(Grant) at price 1240.34 per share. | 7.00 | 2026-10-19 |
| SULZBERGER GABRIELLE | Director | Stock Award(Grant) at price 1164.89 per share. | 4.00 | 2026-09-21 |
| LUCIANO JUAN R | Director | Stock Award(Grant) at price 1164.89 per share. | 13.00 | 2026-09-21 |
| ALVAREZ RALPH | Director | Stock Award(Grant) at price 1164.89 per share. | 10.00 | 2026-09-21 |
| FYRWALD J. ERIK | Director | Stock Award(Grant) at price 1164.89 per share. | 8.00 | 2026-09-21 |
| SEYMOUR MELISSA | Officer | Stock Gift at price 0.00 per share. | 29.00 | 2026-09-09 |
| HERNANDEZ EDGARDO | Officer | Stock Gift at price 0.00 per share. | 13.00 | 2026-09-02 |
| DOZIER ERIC | Officer | Stock Gift at price 0.00 per share. | 216.00 | 2026-09-02 |
| SULZBERGER GABRIELLE | Director | Stock Award(Grant) at price 1183.16 per share. | 4.00 | 2026-08-17 |
Analyst ratings
Consensus score 1.61 (1 = strong buy, 5 = sell) · mean target 1331.55
- Leerink PartnersOutperformmain2026-10-21
- RBC CapitalOutperformreit2026-10-12
- Cantor FitzgeraldOverweightmain2026-10-08
- Morgan StanleyOverweightmain2026-10-07
- JP MorganOverweightmain2026-09-28
- TD CowenBuyreit2026-09-22
- GuggenheimBuymain2026-09-18
- HSBCReducemain2026-09-10
- Truist SecuritiesBuymain2026-08-07
- Wells FargoOverweightmain2026-08-06
Earnings
Next report: 2026-10-29
| Quarter | EPS actual | EPS estimate | Surprise |
|---|---|---|---|
| 3Q2025 | 7.02 | 5.89 | 1.13 |
| 4Q2025 | 7.54 | 6.91 | 0.63 |
| 1Q2026 | 8.55 | 6.79 | 1.76 |
| 2Q2026 | 8.38 | 6.58 | 1.80 |
SEC filings
- 8-KCorporate Changes & Voting Matters2026-08-05Open
- 11-KAnnual report of employee stock purchase2026-06-23Open
- 8-KCorporate Changes & Voting Matters2026-05-20Open
- SDSpecialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)2026-05-11Open
- 8-KCorporate Changes & Voting Matters2026-05-07Open
- 10-QPeriodic Financial Reports2026-04-30Open
- DFAN14AProxy Statements2026-03-31Open
- DEF 14AProxy Statements2026-03-20Open
- PRE 14AProxy Statements2026-03-06Open
- 10-KPeriodic Financial Reports2026-02-12Open
Latest LLY news
- Eli Lilly's Next-Generation Ovarian Cancer Drug Shows 79% Response Rate, 100% Disease Control In New Data
The results come as Lilly continues to test Sofe-M in different types of ovarian cancer, with multiple Phase 3 trials now underway.
Sat, 24 Oct 2026 11:39:15 +0000
- Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026
Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its investigational folate receptor alpha (FRα) antibody-drug conjugate (ADC) sofetabart mipitecan (Sofe-M) plus bevacizumab achieved a confirmed objective response rate (cORR) of 79% and a disease control rate (DCR) of 100% in patients with platinum-sensitive ovarian cancer (PSOC). A cORR of 79% or higher was seen in both poly (ADP-ribose) polymerase inhibitor (PARPi)-treated and PARPi-naïve patients. These data wil
Sat, 24 Oct 2026 06:30:00 +0000
- 2 Growth Stocks to Hold for the Next Decade (Hint: These Aren’t AI Stocks)
These drugmakers are capitalizing on their pipeline successes.
Fri, 23 Oct 2026 20:05:02 +0000
- Goldman Sachs resets Eli Lilly 12-month stock price target before earnings
Wall Street expects strong numbers from LLY, but Goldman says one figure will decide the reaction.
Fri, 23 Oct 2026 19:37:00 +0000
- Eli Lilly Gained 10% in a Week to a New 52-Week High. Is There Room to Run?
Key TakeawaysEli Lilly stock rose 10% in the week through Tuesday’s close to a record, while the S&P 500 fell 1. 1% and the Nasdaq 100 fell 3.
Fri, 23 Oct 2026 18:16:22 +0000
- Eli Lilly (LLY) Builds In Richmond As Fair Value Still Sits Higher
Eli Lilly (LLY) just put a shovel in the ground on a new US$5b manufacturing hub near Richmond, Virginia, a fully integrated site for active ingredients and finished antibody drug conjugate medicines. Eli Lilly shares have been on a strong run, with a 30 day share price return of 11.67% and a year to date share price gain of 20.95%. The 1 year total shareholder return of 60.15% and 5 year total shareholder return of 439.71% point to powerful longer term momentum that recent drug data,...
Fri, 23 Oct 2026 18:11:16 +0000
- JP Morgan Expects Emerging Market Weight Loss Drug Sales To Reach $22 Billion
Key Stats for Eli Lilly StockPrice change for Eli Lilly stock in last 6 months: 42%$LLY Stock Price as of Oct. 22: $130752-Week High: $1321$LLY Stock Price Target: $1332__Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)__>>> What Happened?J.
Fri, 23 Oct 2026 16:59:59 +0000
- Polen Focus Growth Strategy Trims Eli Lilly and Company (LLY) While Maintaining Confidence in Its Outlook
Polen Capital, an investment management company, released its “Polen Focus Growth Strategy” Q3 2026 investor letter. A copy of the letter can be downloaded here. The fund outperformed the Russell 1000 Growth Index in the third quarter of 2026, as investors began distinguishing between businesses vulnerable to artificial intelligence disruption and those positioned to benefit […]
Fri, 23 Oct 2026 15:05:56 +0000